King Luther Capital Management Corp Purchases 20,650 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

King Luther Capital Management Corp boosted its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 0.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,225,790 shares of the company’s stock after acquiring an additional 20,650 shares during the quarter. King Luther Capital Management Corp’s holdings in scPharmaceuticals were worth $10,150,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SCPH. Virtu Financial LLC bought a new position in shares of scPharmaceuticals during the 1st quarter worth $90,000. Balanced Rock Investment Advisors LLC lifted its holdings in shares of scPharmaceuticals by 10.3% during the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock worth $275,000 after purchasing an additional 5,882 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of scPharmaceuticals by 266.7% in the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after acquiring an additional 52,870 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of scPharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock worth $375,000 after buying an additional 11,269 shares during the last quarter. Finally, Bank of Montreal Can acquired a new stake in shares of scPharmaceuticals during the 2nd quarter worth approximately $1,544,000. 89.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, November 14th. Craig Hallum dropped their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

scPharmaceuticals Stock Up 3.0 %

Shares of NASDAQ SCPH opened at $3.46 on Friday. scPharmaceuticals Inc. has a 52-week low of $3.08 and a 52-week high of $6.71. The business’s 50 day moving average is $4.36 and its two-hundred day moving average is $4.46. The firm has a market cap of $173.14 million, a price-to-earnings ratio of -1.82 and a beta of 0.15. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.